1-[2-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]ethoxy]propan-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[2-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]ethoxy]propan-2-one
• 英文别名: 1-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]propan-2-one
• 化学式: C₁₁H₂₃NO₅
• 分子量: 249.3
• InChiKey: CODRDUPOGJREHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  17
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME
  申请人：Industrial Technology Research Institute

  公开号：US20180169262A1

  公开（公告）日：2018-06-21

  A linker-drug represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), C is a conjugator, L is a linker unit, D is a toxin unit, and n is an integer ranging from 1 to 4. The structure of the conjugator is represented by formula (II). In formula (II), X is a leaving group, each of R 1 and R 2 is independently a single bond or —NH—, and Z is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) employing the above linker-drug is also provided.

  提供由式（I）表示的连接药物或其药学上可接受的盐或溶剂。在式（I）中，C是一个结合物，L是一个连接单元，D是一个毒素单元，n是一个从1到4的整数。结合物的结构由式（II）表示。在式（II）中，X是一个离去基团，R1和R2中的每一个独立地是一个单键或—NH—，Z是取代芳基、杂环芳基、直链烷基、环烷基、杂环烷基或它们的组合。抗体通过抗体的半胱氨酸残基与连接单元结合。还提供了使用上述连接药物的抗体-药物结合物（ADC）。
• PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS
  申请人：Flynn Gary A.

  公开号：US20140228367A1

  公开（公告）日：2014-08-14

  The present disclosure relates to compounds of the Formula (I): and pharmaceutically acceptable salts, as kinase modulators, compatible with the Type-II inhibition of kinases.

  本公开涉及式（I）的化合物及其药学上可接受的盐，作为酶调节剂，与激酶的II型抑制相兼容。
• TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
  申请人：Arvinas Operations, Inc.

  公开号：EP3689868A1

  公开（公告）日：2020-08-05

  The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，它们可用作雌激素受体（靶蛋白）的调节剂。特别是，本公开涉及双功能化合物，其一端含有 Von Hippel-Lindau 配体、cereblon 配体、凋亡蛋白抑制剂配体、小鼠双敏同源物 2 配体或其组合中的至少一种、其一端与相应的 E3 泛素连接酶结合，另一端与靶蛋白结合，从而将靶蛋白置于泛素连接酶附近，以实现对靶蛋白的降解（和抑制）。本公开物具有与降解/抑制靶蛋白相关的广泛药理活性。本公开的化合物和组合物可以治疗或预防因目标蛋白聚集或积聚而导致的疾病或失调。
• Linker-drug and antibody-drug conjugate (ADC) employing the same
  申请人：Industrial Technology Research Institute

  公开号：US10864279B2

  公开（公告）日：2020-12-15

  A linker-drug represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), C is a conjugator, L is a linker unit, D is a toxin unit, and n is an integer ranging from 1 to 4. The structure of the conjugator is represented by formula (II). In formula (II), X is a leaving group, each of R1 and R2 is independently a single bond or —NH—, and Z is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) employing the above linker-drug is also provided.

  本发明提供了一种由式（I）表示的连接剂-药物或其药学上可接受的盐或溶液。在式 (I) 中，C 是共轭物，L 是连接体单元，D 是毒素单元，n 是 1 至 4 的整数。在式 (II) 中，X 是离去基团，R1 和 R2 各自独立地是单键或-NH-，Z 是取代的芳基、杂芳基、直链烷基、环烷基、杂环烷基或它们的组合。抗体通过抗体的半胱氨酸残基与连接体单元连接。还提供了一种采用上述连接体-药物的抗体-药物共轭物（ADC）。
• [EN] IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE<br/>[FR] MODULATEURS DE PROTÉOLYSE À BASE D'IMIDE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：UNIV YALE

  公开号：WO2019148055A9

  公开（公告）日：2019-09-26